CME mice treated with TAK-242 showed a significant improvement in cardiac function and a decrease in micro-infarction area and in apoptotic index when compared with untreated mice, validating TLR4 as a target in this pathology and suggesting treatment with TLR4 inhibitors as an efficient therapeutic approach. This evidence concerns the gene TLR4 and infarction.